SpyGlass Pharma

Chronic eye condition biotech SpyGlass Pharma files for a $100 million IPO February 6, 2026 News Chronic eye condition biotech SpyGlass Pharma prices IPO at $16 midpoint SpyGlass Pharma, a Phase 3 biotech developing implanted drug-devices for chronic eye conditions,... Read more